Clinical trial Recruiting at 1 site Observational Ages Any age to 45 Men only

Testosterone levels and coronary lesion complexity in young men

Official title: Impact of Serum Testosterone Level on Angiographic Complexity of Coronary Lesions in Premature Ischemic Egyptian Males

Run by Sohag University · NCT07076771 · Data updated 2026-11-12

We will test whether blood testosterone levels are linked to how complex coronary artery blockages are in men under 45 with premature ischemic heart disease.

Quick facts

Study typeObservational
AgesAny age to 45 Years
SexMen only
Enrollment50 (estimated)
SponsorSohag University
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Sohag)
StatusRecruiting
StartedJanuary 1, 2025
Main results expectedAugust 1, 2025
Study endsAugust 1, 2025
Registry record updatedJuly 22, 2025
Trial IDNCT07076771 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Men younger than 45 diagnosed with premature ischemic heart disease who are undergoing elective coronary angiography and have not used testosterone therapy or anabolic steroids.

Probably not a fit

Patients with a recent acute coronary syndrome, prior hypogonadism or testosterone/anabolic steroid use, active cancer, significant liver or kidney disease, or on medications that affect sex hormones are excluded and unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study enrolls men under 45 with premature ischemic heart disease who are scheduled for elective coronary angiography. Investigators will measure serum testosterone and determine lesion complexity using the SYNTAX score from the angiograms. The analysis will look for associations between testosterone level and angiographic complexity while adjusting for traditional cardiovascular risk factors. Results aim to clarify whether hormonal status relates to the severity and complexity of early-onset coronary artery disease.

Why it matters

Potential benefit: If a link is confirmed, measuring testosterone could help identify young men at higher risk of complex coronary disease and inform early risk-reduction strategies.

How similar studies have gone: Prior observational work has linked low testosterone to worse metabolic and cardiovascular risk profiles, but direct evidence tying testosterone to angiographic lesion complexity is limited, so this is largely exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male patients aged \<45 years.
* Diagnosed with premature ischemic heart disease.
* Undergoing elective coronary angiography for suspected coronary artery disease (CAD) .

Exclusion Criteria:

* History of acute coronary syndrome within the preceding 3 months.
* Prior diagnosis of hypogonadism or history of testosterone replacement therapy or anabolic steroid use.
* Active neoplasm or history of chemotherapy.
* Known hepatic cirrhosis, chronic kidney disease, or end-stage renal disease.
* Use of medications known to affect sex hormone levels (e.g., spironolactone, ketoconazole).
* Endocrine disorders such as sickle cell anemia or celiac disease.

Where it's running

  • Sohag University
    Sohag, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.